AustralieFrV1, PubMed, Checkpoint, bibRecord, 002C56

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Identifieur interne : 002C56 ( PubMed/Checkpoint ); précédent : 002C55; suivant : 002C57

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Auteurs : Aimée R. Kreimer [États-Unis] ; Frank Struyf [Belgique] ; Maria Rowena Del Rosario-Raymundo [Philippines] ; Allan Hildesheim [États-Unis] ; S Rachel Skinner [Australie] ; Sholom Wacholder [États-Unis] ; Suzanne M. Garland [Australie] ; Rolando Herrero [France] ; Marie-Pierre David [Belgique] ; Cosette M. Wheeler [États-Unis] ; Paula González ; Silvia Jiménez ; Douglas R. Lowy ; Ligia A. Pinto ; Caroline Porras ; Ana Cecilia Rodriguez ; Mahboobeh Safaeian ; Mark Schiffman ; John T. Schiller ; John Schussler ; Mark E. Sherman ; F Xavier Bosch ; Xavier Castellsague ; Archana Chatterjee ; Song-Nan Chow ; Dominique Descamps ; Francisco Diaz-Mitoma ; Gary Dubin ; Maria Julieta Germar ; Diane M. Harper ; David J M. Lewis ; Genara Limson ; Paulo Naud ; Klaus Peters ; Willy A J. Poppe ; Brian Ramjattan ; Barbara Romanowski ; Jorge Salmeron ; Tino F. Schwarz ; Julio C. Teixeira ; Wiebren A A. Tjalma

Source :

The Lancet. Oncology [ 1474-5488 ] ; 2015.

RBID : pubmed:26071347

Descripteurs français

KwdFr :
- Adjuvants immunologiques (administration et posologie), Adolescent, Adulte, Calendrier d'administration des médicaments, Costa Rica, Facteurs de l'âge, Facteurs temps, Femelle, Humains, Infections à papillomavirus (), Jeune adulte, Méthode en double aveugle, Néoplasie intraépithéliale cervicale (), Néoplasie intraépithéliale cervicale (virologie), Papillomavirus humain de type 16 (immunologie), Papillomavirus humain de type 16 (isolement et purification), Papillomavirus humain de type 18 (immunologie), Papillomavirus humain de type 18 (isolement et purification), Relation dose-effet des médicaments, Résultat thérapeutique, Vaccination (), Vaccins contre les papillomavirus (administration et posologie), États-Unis d'Amérique, Études de suivi, Évaluation des risques.
MESH :
- administration et posologie : Adjuvants immunologiques, Vaccins contre les papillomavirus.
- immunologie : Papillomavirus humain de type 16, Papillomavirus humain de type 18.
- isolement et purification : Papillomavirus humain de type 16, Papillomavirus humain de type 18.
- virologie : Néoplasie intraépithéliale cervicale.
- Adolescent, Adulte, Calendrier d'administration des médicaments, Costa Rica, Facteurs de l'âge, Facteurs temps, Femelle, Humains, Infections à papillomavirus, Jeune adulte, Méthode en double aveugle, Néoplasie intraépithéliale cervicale, Relation dose-effet des médicaments, Résultat thérapeutique, Vaccination, États-Unis d'Amérique, Études de suivi, Évaluation des risques.
Wicri :
- geographic : Costa Rica, États-Unis.

English descriptors

KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adolescent, Adult, Age Factors, Cervical Intraepithelial Neoplasia (prevention & control), Cervical Intraepithelial Neoplasia (virology), Costa Rica, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Human papillomavirus 16 (immunology), Human papillomavirus 16 (isolation & purification), Human papillomavirus 18 (immunology), Human papillomavirus 18 (isolation & purification), Humans, Papillomavirus Infections (prevention & control), Papillomavirus Vaccines (administration & dosage), Risk Assessment, Time Factors, Treatment Outcome, United States, Vaccination (methods), Young Adult.
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Papillomavirus Vaccines.
- geographic : Costa Rica, United States.
- immunology : Human papillomavirus 16, Human papillomavirus 18.
- isolation & purification : Human papillomavirus 16, Human papillomavirus 18.
- methods : Vaccination.
- prevention & control : Cervical Intraepithelial Neoplasia, Papillomavirus Infections.
- virology : Cervical Intraepithelial Neoplasia.
- Adolescent, Adult, Age Factors, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Risk Assessment, Time Factors, Treatment Outcome, Young Adult.

Abstract

There is some evidence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dose regimen. The main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV types, by number of doses received.

DOI: 10.1016/S1470-2045(15)00047-9
PubMed: 26071347

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002B54
to stream PubMed, to step Curation: 002A82

Links to Exploration step

pubmed:26071347

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.</title>
<author><name sortKey="Kreimer, Aimee R" sort="Kreimer, Aimee R" uniqKey="Kreimer A" first="Aimée R" last="Kreimer">Aimée R. Kreimer</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: kreimera@mail.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Struyf, Frank" sort="Struyf, Frank" uniqKey="Struyf F" first="Frank" last="Struyf">Frank Struyf</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Rosario Raymundo, Maria Rowena" sort="Del Rosario Raymundo, Maria Rowena" uniqKey="Del Rosario Raymundo M" first="Maria Rowena" last="Del Rosario-Raymundo">Maria Rowena Del Rosario-Raymundo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Philippines.</nlm:affiliation>
<country xml:lang="fr">Philippines</country>
<wicri:regionArea>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City</wicri:regionArea>
<wicri:noRegion>San Pablo City</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hildesheim, Allan" sort="Hildesheim, Allan" uniqKey="Hildesheim A" first="Allan" last="Hildesheim">Allan Hildesheim</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Skinner, S Rachel" sort="Skinner, S Rachel" uniqKey="Skinner S" first="S Rachel" last="Skinner">S Rachel Skinner</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA, Australia; Sydney University Discipline of Paediatrics and Child Health, Children's Hospital at Westmead, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA, Australia; Sydney University Discipline of Paediatrics and Child Health, Children's Hospital at Westmead, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wacholder, Sholom" sort="Wacholder, Sholom" uniqKey="Wacholder S" first="Sholom" last="Wacholder">Sholom Wacholder</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name>
<affiliation wicri:level="4"><nlm:affiliation>Microbiology and Infectious Diseases Department, Royal Women's Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Murdoch Childrens Research Institute Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Microbiology and Infectious Diseases Department, Royal Women's Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Murdoch Childrens Research Institute Melbourne, VIC</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Herrero, Rolando" sort="Herrero, Rolando" uniqKey="Herrero R" first="Rolando" last="Herrero">Rolando Herrero</name>
<affiliation wicri:level="3"><nlm:affiliation>Proyecto Epidemiologico Guanacaste, San José, Costa Rica; Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Proyecto Epidemiologico Guanacaste, San José, Costa Rica; Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="David, Marie Pierre" sort="David, Marie Pierre" uniqKey="David M" first="Marie-Pierre" last="David">Marie-Pierre David</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wheeler, Cosette M" sort="Wheeler, Cosette M" uniqKey="Wheeler C" first="Cosette M" last="Wheeler">Cosette M. Wheeler</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. Electronic address: cwheeler@salud.unm.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM</wicri:regionArea>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gonzalez, Paula" sort="Gonzalez, Paula" uniqKey="Gonzalez P" first="Paula" last="González">Paula González</name>
</author>
<author><name sortKey="Jimenez, Silvia" sort="Jimenez, Silvia" uniqKey="Jimenez S" first="Silvia" last="Jiménez">Silvia Jiménez</name>
</author>
<author><name sortKey="Lowy, Douglas R" sort="Lowy, Douglas R" uniqKey="Lowy D" first="Douglas R" last="Lowy">Douglas R. Lowy</name>
</author>
<author><name sortKey="Pinto, Ligia A" sort="Pinto, Ligia A" uniqKey="Pinto L" first="Ligia A" last="Pinto">Ligia A. Pinto</name>
</author>
<author><name sortKey="Porras, Caroline" sort="Porras, Caroline" uniqKey="Porras C" first="Caroline" last="Porras">Caroline Porras</name>
</author>
<author><name sortKey="Rodriguez, Ana Cecilia" sort="Rodriguez, Ana Cecilia" uniqKey="Rodriguez A" first="Ana Cecilia" last="Rodriguez">Ana Cecilia Rodriguez</name>
</author>
<author><name sortKey="Safaeian, Mahboobeh" sort="Safaeian, Mahboobeh" uniqKey="Safaeian M" first="Mahboobeh" last="Safaeian">Mahboobeh Safaeian</name>
</author>
<author><name sortKey="Schiffman, Mark" sort="Schiffman, Mark" uniqKey="Schiffman M" first="Mark" last="Schiffman">Mark Schiffman</name>
</author>
<author><name sortKey="Schiller, John T" sort="Schiller, John T" uniqKey="Schiller J" first="John T" last="Schiller">John T. Schiller</name>
</author>
<author><name sortKey="Schussler, John" sort="Schussler, John" uniqKey="Schussler J" first="John" last="Schussler">John Schussler</name>
</author>
<author><name sortKey="Sherman, Mark E" sort="Sherman, Mark E" uniqKey="Sherman M" first="Mark E" last="Sherman">Mark E. Sherman</name>
</author>
<author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F Xavier" last="Bosch">F Xavier Bosch</name>
</author>
<author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsague">Xavier Castellsague</name>
</author>
<author><name sortKey="Chatterjee, Archana" sort="Chatterjee, Archana" uniqKey="Chatterjee A" first="Archana" last="Chatterjee">Archana Chatterjee</name>
</author>
<author><name sortKey="Chow, Song Nan" sort="Chow, Song Nan" uniqKey="Chow S" first="Song-Nan" last="Chow">Song-Nan Chow</name>
</author>
<author><name sortKey="Descamps, Dominique" sort="Descamps, Dominique" uniqKey="Descamps D" first="Dominique" last="Descamps">Dominique Descamps</name>
</author>
<author><name sortKey="Diaz Mitoma, Francisco" sort="Diaz Mitoma, Francisco" uniqKey="Diaz Mitoma F" first="Francisco" last="Diaz-Mitoma">Francisco Diaz-Mitoma</name>
</author>
<author><name sortKey="Dubin, Gary" sort="Dubin, Gary" uniqKey="Dubin G" first="Gary" last="Dubin">Gary Dubin</name>
</author>
<author><name sortKey="Germar, Maria Julieta" sort="Germar, Maria Julieta" uniqKey="Germar M" first="Maria Julieta" last="Germar">Maria Julieta Germar</name>
</author>
<author><name sortKey="Harper, Diane M" sort="Harper, Diane M" uniqKey="Harper D" first="Diane M" last="Harper">Diane M. Harper</name>
</author>
<author><name sortKey="Lewis, David J M" sort="Lewis, David J M" uniqKey="Lewis D" first="David J M" last="Lewis">David J M. Lewis</name>
</author>
<author><name sortKey="Limson, Genara" sort="Limson, Genara" uniqKey="Limson G" first="Genara" last="Limson">Genara Limson</name>
</author>
<author><name sortKey="Naud, Paulo" sort="Naud, Paulo" uniqKey="Naud P" first="Paulo" last="Naud">Paulo Naud</name>
</author>
<author><name sortKey="Peters, Klaus" sort="Peters, Klaus" uniqKey="Peters K" first="Klaus" last="Peters">Klaus Peters</name>
</author>
<author><name sortKey="Poppe, Willy A J" sort="Poppe, Willy A J" uniqKey="Poppe W" first="Willy A J" last="Poppe">Willy A J. Poppe</name>
</author>
<author><name sortKey="Ramjattan, Brian" sort="Ramjattan, Brian" uniqKey="Ramjattan B" first="Brian" last="Ramjattan">Brian Ramjattan</name>
</author>
<author><name sortKey="Romanowski, Barbara" sort="Romanowski, Barbara" uniqKey="Romanowski B" first="Barbara" last="Romanowski">Barbara Romanowski</name>
</author>
<author><name sortKey="Salmeron, Jorge" sort="Salmeron, Jorge" uniqKey="Salmeron J" first="Jorge" last="Salmeron">Jorge Salmeron</name>
</author>
<author><name sortKey="Schwarz, Tino F" sort="Schwarz, Tino F" uniqKey="Schwarz T" first="Tino F" last="Schwarz">Tino F. Schwarz</name>
</author>
<author><name sortKey="Teixeira, Julio C" sort="Teixeira, Julio C" uniqKey="Teixeira J" first="Julio C" last="Teixeira">Julio C. Teixeira</name>
</author>
<author><name sortKey="Tjalma, Wiebren A A" sort="Tjalma, Wiebren A A" uniqKey="Tjalma W" first="Wiebren A A" last="Tjalma">Wiebren A A. Tjalma</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26071347</idno>
<idno type="pmid">26071347</idno>
<idno type="doi">10.1016/S1470-2045(15)00047-9</idno>
<idno type="wicri:Area/PubMed/Corpus">002B54</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002B54</idno>
<idno type="wicri:Area/PubMed/Curation">002A82</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002A82</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A82</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A82</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.</title>
<author><name sortKey="Kreimer, Aimee R" sort="Kreimer, Aimee R" uniqKey="Kreimer A" first="Aimée R" last="Kreimer">Aimée R. Kreimer</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: kreimera@mail.nih.gov.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Struyf, Frank" sort="Struyf, Frank" uniqKey="Struyf F" first="Frank" last="Struyf">Frank Struyf</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Rosario Raymundo, Maria Rowena" sort="Del Rosario Raymundo, Maria Rowena" uniqKey="Del Rosario Raymundo M" first="Maria Rowena" last="Del Rosario-Raymundo">Maria Rowena Del Rosario-Raymundo</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Philippines.</nlm:affiliation>
<country xml:lang="fr">Philippines</country>
<wicri:regionArea>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City</wicri:regionArea>
<wicri:noRegion>San Pablo City</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hildesheim, Allan" sort="Hildesheim, Allan" uniqKey="Hildesheim A" first="Allan" last="Hildesheim">Allan Hildesheim</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Skinner, S Rachel" sort="Skinner, S Rachel" uniqKey="Skinner S" first="S Rachel" last="Skinner">S Rachel Skinner</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA, Australia; Sydney University Discipline of Paediatrics and Child Health, Children's Hospital at Westmead, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA, Australia; Sydney University Discipline of Paediatrics and Child Health, Children's Hospital at Westmead, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wacholder, Sholom" sort="Wacholder, Sholom" uniqKey="Wacholder S" first="Sholom" last="Wacholder">Sholom Wacholder</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name>
<affiliation wicri:level="4"><nlm:affiliation>Microbiology and Infectious Diseases Department, Royal Women's Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Murdoch Childrens Research Institute Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Microbiology and Infectious Diseases Department, Royal Women's Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Murdoch Childrens Research Institute Melbourne, VIC</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Herrero, Rolando" sort="Herrero, Rolando" uniqKey="Herrero R" first="Rolando" last="Herrero">Rolando Herrero</name>
<affiliation wicri:level="3"><nlm:affiliation>Proyecto Epidemiologico Guanacaste, San José, Costa Rica; Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Proyecto Epidemiologico Guanacaste, San José, Costa Rica; Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="David, Marie Pierre" sort="David, Marie Pierre" uniqKey="David M" first="Marie-Pierre" last="David">Marie-Pierre David</name>
<affiliation wicri:level="1"><nlm:affiliation>GSK Vaccines, Wavre, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>GSK Vaccines, Wavre</wicri:regionArea>
<wicri:noRegion>Wavre</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wheeler, Cosette M" sort="Wheeler, Cosette M" uniqKey="Wheeler C" first="Cosette M" last="Wheeler">Cosette M. Wheeler</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. Electronic address: cwheeler@salud.unm.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM</wicri:regionArea>
<placeName><region type="state">Nouveau-Mexique</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gonzalez, Paula" sort="Gonzalez, Paula" uniqKey="Gonzalez P" first="Paula" last="González">Paula González</name>
</author>
<author><name sortKey="Jimenez, Silvia" sort="Jimenez, Silvia" uniqKey="Jimenez S" first="Silvia" last="Jiménez">Silvia Jiménez</name>
</author>
<author><name sortKey="Lowy, Douglas R" sort="Lowy, Douglas R" uniqKey="Lowy D" first="Douglas R" last="Lowy">Douglas R. Lowy</name>
</author>
<author><name sortKey="Pinto, Ligia A" sort="Pinto, Ligia A" uniqKey="Pinto L" first="Ligia A" last="Pinto">Ligia A. Pinto</name>
</author>
<author><name sortKey="Porras, Caroline" sort="Porras, Caroline" uniqKey="Porras C" first="Caroline" last="Porras">Caroline Porras</name>
</author>
<author><name sortKey="Rodriguez, Ana Cecilia" sort="Rodriguez, Ana Cecilia" uniqKey="Rodriguez A" first="Ana Cecilia" last="Rodriguez">Ana Cecilia Rodriguez</name>
</author>
<author><name sortKey="Safaeian, Mahboobeh" sort="Safaeian, Mahboobeh" uniqKey="Safaeian M" first="Mahboobeh" last="Safaeian">Mahboobeh Safaeian</name>
</author>
<author><name sortKey="Schiffman, Mark" sort="Schiffman, Mark" uniqKey="Schiffman M" first="Mark" last="Schiffman">Mark Schiffman</name>
</author>
<author><name sortKey="Schiller, John T" sort="Schiller, John T" uniqKey="Schiller J" first="John T" last="Schiller">John T. Schiller</name>
</author>
<author><name sortKey="Schussler, John" sort="Schussler, John" uniqKey="Schussler J" first="John" last="Schussler">John Schussler</name>
</author>
<author><name sortKey="Sherman, Mark E" sort="Sherman, Mark E" uniqKey="Sherman M" first="Mark E" last="Sherman">Mark E. Sherman</name>
</author>
<author><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F Xavier" last="Bosch">F Xavier Bosch</name>
</author>
<author><name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsague">Xavier Castellsague</name>
</author>
<author><name sortKey="Chatterjee, Archana" sort="Chatterjee, Archana" uniqKey="Chatterjee A" first="Archana" last="Chatterjee">Archana Chatterjee</name>
</author>
<author><name sortKey="Chow, Song Nan" sort="Chow, Song Nan" uniqKey="Chow S" first="Song-Nan" last="Chow">Song-Nan Chow</name>
</author>
<author><name sortKey="Descamps, Dominique" sort="Descamps, Dominique" uniqKey="Descamps D" first="Dominique" last="Descamps">Dominique Descamps</name>
</author>
<author><name sortKey="Diaz Mitoma, Francisco" sort="Diaz Mitoma, Francisco" uniqKey="Diaz Mitoma F" first="Francisco" last="Diaz-Mitoma">Francisco Diaz-Mitoma</name>
</author>
<author><name sortKey="Dubin, Gary" sort="Dubin, Gary" uniqKey="Dubin G" first="Gary" last="Dubin">Gary Dubin</name>
</author>
<author><name sortKey="Germar, Maria Julieta" sort="Germar, Maria Julieta" uniqKey="Germar M" first="Maria Julieta" last="Germar">Maria Julieta Germar</name>
</author>
<author><name sortKey="Harper, Diane M" sort="Harper, Diane M" uniqKey="Harper D" first="Diane M" last="Harper">Diane M. Harper</name>
</author>
<author><name sortKey="Lewis, David J M" sort="Lewis, David J M" uniqKey="Lewis D" first="David J M" last="Lewis">David J M. Lewis</name>
</author>
<author><name sortKey="Limson, Genara" sort="Limson, Genara" uniqKey="Limson G" first="Genara" last="Limson">Genara Limson</name>
</author>
<author><name sortKey="Naud, Paulo" sort="Naud, Paulo" uniqKey="Naud P" first="Paulo" last="Naud">Paulo Naud</name>
</author>
<author><name sortKey="Peters, Klaus" sort="Peters, Klaus" uniqKey="Peters K" first="Klaus" last="Peters">Klaus Peters</name>
</author>
<author><name sortKey="Poppe, Willy A J" sort="Poppe, Willy A J" uniqKey="Poppe W" first="Willy A J" last="Poppe">Willy A J. Poppe</name>
</author>
<author><name sortKey="Ramjattan, Brian" sort="Ramjattan, Brian" uniqKey="Ramjattan B" first="Brian" last="Ramjattan">Brian Ramjattan</name>
</author>
<author><name sortKey="Romanowski, Barbara" sort="Romanowski, Barbara" uniqKey="Romanowski B" first="Barbara" last="Romanowski">Barbara Romanowski</name>
</author>
<author><name sortKey="Salmeron, Jorge" sort="Salmeron, Jorge" uniqKey="Salmeron J" first="Jorge" last="Salmeron">Jorge Salmeron</name>
</author>
<author><name sortKey="Schwarz, Tino F" sort="Schwarz, Tino F" uniqKey="Schwarz T" first="Tino F" last="Schwarz">Tino F. Schwarz</name>
</author>
<author><name sortKey="Teixeira, Julio C" sort="Teixeira, Julio C" uniqKey="Teixeira J" first="Julio C" last="Teixeira">Julio C. Teixeira</name>
</author>
<author><name sortKey="Tjalma, Wiebren A A" sort="Tjalma, Wiebren A A" uniqKey="Tjalma W" first="Wiebren A A" last="Tjalma">Wiebren A A. Tjalma</name>
</author>
</analytic>
<series><title level="j">The Lancet. Oncology</title>
<idno type="eISSN">1474-5488</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Age Factors</term>
<term>Cervical Intraepithelial Neoplasia (prevention & control)</term>
<term>Cervical Intraepithelial Neoplasia (virology)</term>
<term>Costa Rica</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Human papillomavirus 16 (immunology)</term>
<term>Human papillomavirus 16 (isolation & purification)</term>
<term>Human papillomavirus 18 (immunology)</term>
<term>Human papillomavirus 18 (isolation & purification)</term>
<term>Humans</term>
<term>Papillomavirus Infections (prevention & control)</term>
<term>Papillomavirus Vaccines (administration & dosage)</term>
<term>Risk Assessment</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>United States</term>
<term>Vaccination (methods)</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Adolescent</term>
<term>Adulte</term>
<term>Calendrier d'administration des médicaments</term>
<term>Costa Rica</term>
<term>Facteurs de l'âge</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à papillomavirus ()</term>
<term>Jeune adulte</term>
<term>Méthode en double aveugle</term>
<term>Néoplasie intraépithéliale cervicale ()</term>
<term>Néoplasie intraépithéliale cervicale (virologie)</term>
<term>Papillomavirus humain de type 16 (immunologie)</term>
<term>Papillomavirus humain de type 16 (isolement et purification)</term>
<term>Papillomavirus humain de type 18 (immunologie)</term>
<term>Papillomavirus humain de type 18 (isolement et purification)</term>
<term>Relation dose-effet des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Vaccination ()</term>
<term>Vaccins contre les papillomavirus (administration et posologie)</term>
<term>États-Unis d'Amérique</term>
<term>Études de suivi</term>
<term>Évaluation des risques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Papillomavirus Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Costa Rica</term>
<term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Vaccins contre les papillomavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Papillomavirus humain de type 16</term>
<term>Papillomavirus humain de type 18</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Human papillomavirus 16</term>
<term>Human papillomavirus 18</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Human papillomavirus 16</term>
<term>Human papillomavirus 18</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Papillomavirus humain de type 16</term>
<term>Papillomavirus humain de type 18</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cervical Intraepithelial Neoplasia</term>
<term>Papillomavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Néoplasie intraépithéliale cervicale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Cervical Intraepithelial Neoplasia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Age Factors</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Risk Assessment</term>
<term>Time Factors</term>
<term>Treatment Outcome</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Calendrier d'administration des médicaments</term>
<term>Costa Rica</term>
<term>Facteurs de l'âge</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à papillomavirus</term>
<term>Jeune adulte</term>
<term>Méthode en double aveugle</term>
<term>Néoplasie intraépithéliale cervicale</term>
<term>Relation dose-effet des médicaments</term>
<term>Résultat thérapeutique</term>
<term>Vaccination</term>
<term>États-Unis d'Amérique</term>
<term>Études de suivi</term>
<term>Évaluation des risques</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Costa Rica</term>
<term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is some evidence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dose regimen. The main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV types, by number of doses received.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26071347</PMID>
<DateCreated><Year>2015</Year>
<Month>07</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>12</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>16</Volume>
<Issue>7</Issue>
<PubDate><Year>2015</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>The Lancet. Oncology</Title>
<ISOAbbreviation>Lancet Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.</ArticleTitle>
<Pagination><MedlinePgn>775-86</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(15)00047-9</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S1470-2045(15)00047-9</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is some evidence to suggest that one or two doses of the HPV vaccine provides similar protection to the three-dose regimen. The main aim of the study was to ascertain HPV-16/18 vaccine efficacy in both full and naive cohorts and to explore protection conferred against non-vaccine HPV types, by number of doses received.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Summary data from the Costa Rica Vaccine Trial (CVT; NCT00128661) and ~the PATRICIA trial (NCT001226810), two phase 3, double-blind, randomised controlled clinical trials of the HPV-16/18 AS04-adjuvanted vaccine in young women, were combined in a post-hoc analysis (GlaxoSmithKline [GSK] e-track number 202142) to investigate the efficacy of fewer than three doses of the HPV-16/18 vaccine after 4 years of follow-up. Women were randomly assigned to receive three doses of the HPV-16/18 vaccine or to a control vaccine; yet, some received fewer doses. After exclusion of women with less than 12 months of follow-up or those who were HPV-16/18 DNA-positive at enrolment (for the HPV-16/18 endpoint), we calculated vaccine efficacy against one-time detection of incident HPV infections after three, two, and one dose(s). The primary study endpoint was one-time detection of first incident HPV-16/18 infections accumulated during the follow-up phase.</AbstractText>
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">We assessed vaccine efficacy against incident HPV-16/18 infection in the modified total vaccinated cohort (22 327 received three doses, 1185 two doses, 543 one dose). Vaccine efficacy against incident HPV-16/18 infections for three doses was 77·0% (95% CI 74·7-79·1), two doses was 76·0% (62·0-85·3), and one dose was 85·7% (70·7-93·7). Vaccine efficacy against incident HPV-31/33/45 infections for three doses was 59·7% (56·0-63·0), two doses was 37·7% (12·4-55·9), and one dose was 36·6% (-5·4 to 62·2). Vaccine efficacy against incident HPV-16/18 infection for two-dose women who received their second dose at 1 month was 75·3% (54·2-87·5) and 82·6% (42·3-96·1) for those who received the second dose at 6 months (CVT data only). Vaccine efficacy against HPV-31/33/45 for two-dose women who received their second dose at 6 months (68·1%, 27·0-87·0; CVT data only), but not those receiving it at one month (10·1%, -42·0 to 43·3), was similar to the three-dose group.</AbstractText>
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">4 years after vaccination of women aged 15-25 years, one and two doses of the HPV-16/18 vaccine seem to protect against cervical HPV-16/18 infections, similar to the protection provided by the three-dose schedule. Two doses separated by 6 months additionally provided some cross-protection. These data argue for a direct assessment of one-dose efficacy of the HPV-16/18 vaccine.</AbstractText>
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">US National Cancer Institute, National Institutes of Health Office of Research on Women's Health, and Ministry of Health of Costa Rica (CVT); GlaxoSmithKline Biologicals SA (PATRICIA).</AbstractText>
<CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kreimer</LastName>
<ForeName>Aimée R</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: kreimera@mail.nih.gov.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Struyf</LastName>
<ForeName>Frank</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Del Rosario-Raymundo</LastName>
<ForeName>Maria Rowena</ForeName>
<Initials>MR</Initials>
<AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, San Pablo Colleges Medical Center, San Pablo City, Philippines.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hildesheim</LastName>
<ForeName>Allan</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Skinner</LastName>
<ForeName>S Rachel</ForeName>
<Initials>SR</Initials>
<AffiliationInfo><Affiliation>Vaccine Trials Group, Telethon Institute for Child Health Research, Perth, WA, Australia; Sydney University Discipline of Paediatrics and Child Health, Children's Hospital at Westmead, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wacholder</LastName>
<ForeName>Sholom</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Garland</LastName>
<ForeName>Suzanne M</ForeName>
<Initials>SM</Initials>
<AffiliationInfo><Affiliation>Microbiology and Infectious Diseases Department, Royal Women's Hospital and Department of Obstetrics and Gynaecology, University of Melbourne, Murdoch Childrens Research Institute Melbourne, VIC, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Herrero</LastName>
<ForeName>Rolando</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>Proyecto Epidemiologico Guanacaste, San José, Costa Rica; Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>David</LastName>
<ForeName>Marie-Pierre</ForeName>
<Initials>MP</Initials>
<AffiliationInfo><Affiliation>GSK Vaccines, Wavre, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wheeler</LastName>
<ForeName>Cosette M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>Departments of Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. Electronic address: cwheeler@salud.unm.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>Costa Rica Vaccine Trial Study Group Authors</CollectiveName>
</Author>
<Author ValidYN="Y"><LastName>González</LastName>
<ForeName>Paula</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jiménez</LastName>
<ForeName>Silvia</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lowy</LastName>
<ForeName>Douglas R</ForeName>
<Initials>DR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pinto</LastName>
<ForeName>Ligia A</ForeName>
<Initials>LA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Porras</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Rodriguez</LastName>
<ForeName>Ana Cecilia</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Safaeian</LastName>
<ForeName>Mahboobeh</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schiffman</LastName>
<ForeName>Mark</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schiller</LastName>
<ForeName>John T</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schussler</LastName>
<ForeName>John</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sherman</LastName>
<ForeName>Mark E</ForeName>
<Initials>ME</Initials>
</Author>
<Author ValidYN="Y"><CollectiveName>PATRICIA Study Group Authors</CollectiveName>
</Author>
<Author ValidYN="Y"><LastName>Bosch</LastName>
<ForeName>F Xavier</ForeName>
<Initials>FX</Initials>
</Author>
<Author ValidYN="Y"><LastName>Castellsague</LastName>
<ForeName>Xavier</ForeName>
<Initials>X</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chatterjee</LastName>
<ForeName>Archana</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chow</LastName>
<ForeName>Song-Nan</ForeName>
<Initials>SN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Descamps</LastName>
<ForeName>Dominique</ForeName>
<Initials>D</Initials>
</Author>
<Author ValidYN="Y"><LastName>Diaz-Mitoma</LastName>
<ForeName>Francisco</ForeName>
<Initials>F</Initials>
</Author>
<Author ValidYN="Y"><LastName>Dubin</LastName>
<ForeName>Gary</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Germar</LastName>
<ForeName>Maria Julieta</ForeName>
<Initials>MJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Harper</LastName>
<ForeName>Diane M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lewis</LastName>
<ForeName>David J M</ForeName>
<Initials>DJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Limson</LastName>
<ForeName>Genara</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Naud</LastName>
<ForeName>Paulo</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Peters</LastName>
<ForeName>Klaus</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Poppe</LastName>
<ForeName>Willy A J</ForeName>
<Initials>WA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ramjattan</LastName>
<ForeName>Brian</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Romanowski</LastName>
<ForeName>Barbara</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Salmeron</LastName>
<ForeName>Jorge</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schwarz</LastName>
<ForeName>Tino F</ForeName>
<Initials>TF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Teixeira</LastName>
<ForeName>Julio C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tjalma</LastName>
<ForeName>Wiebren A A</ForeName>
<Initials>WA</Initials>
</Author>
<Author ValidYN="Y"><CollectiveName>HPV PATRICIA Principal Investigators/Co-Principal Investigator Collaborators</CollectiveName>
</Author>
<Author ValidYN="Y"><CollectiveName>GSK Vaccines Clinical Study Support Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName>
<AccessionNumberList><AccessionNumber>NCT00128661</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<GrantList CompleteYN="Y"><Grant><GrantID>P30 CA118100</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>ZIA CP010177-09</GrantID>
<Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>N01-CP-11005</GrantID>
<Acronym>CP</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>06</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Lancet Oncol</MedlineTA>
<NlmUniqueID>100957246</NlmUniqueID>
<ISSNLinking>1470-2045</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053918">Papillomavirus Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2014 Oct 29;32(47):6303-11</RefSource>
<PMID Version="1">25218297</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2010 Nov;10(11):787-96</RefSource>
<PMID Version="1">20948547</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50</RefSource>
<PMID Version="1">24189371</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(6):e101114</RefSource>
<PMID Version="1">24968002</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hum Vaccin Immunother. 2014;10(12):3435-45</RefSource>
<PMID Version="1">25483701</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2015 Mar;107(3). pii: dju436. doi: 10.1093/jnci/dju436</RefSource>
<PMID Version="1">25650316</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 1998 Dec;153(6):1731-9</RefSource>
<PMID Version="1">9846964</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 1999 Aug;37(8):2508-17</RefSource>
<PMID Version="1">10405393</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Microbiol. 2006 Sep;44(9):3292-8</RefSource>
<PMID Version="1">16954263</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 May 10;356(19):1915-27</RefSource>
<PMID Version="1">17494925</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Jun 30;369(9580):2161-70</RefSource>
<PMID Version="1">17602732</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2008 Sep 2;26(37):4795-808</RefSource>
<PMID Version="1">18640170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet. 2009 Jul 25;374(9686):301-14</RefSource>
<PMID Version="1">19586656</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Nov;11(11):1048-56</RefSource>
<PMID Version="1">20952254</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2011 Mar 3;29(11):2011-4</RefSource>
<PMID Version="1">21241731</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2011 Oct 5;103(19):1444-51</RefSource>
<PMID Version="1">21908768</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hum Vaccin. 2011 Dec;7(12):1374-86</RefSource>
<PMID Version="1">22048171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2015 May 1;211(9):1373-5</RefSource>
<PMID Version="1">25420478</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2013 May 1;309(17):1793-802</RefSource>
<PMID Version="1">23632723</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2015 Feb 19;372(8):711-23</RefSource>
<PMID Version="1">25693011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hum Vaccin Immunother. 2014;10(5):1155-65</RefSource>
<PMID Version="1">24576907</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Jan;13(1):100-10</RefSource>
<PMID Version="1">22075170</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Jan;13(1):89-99</RefSource>
<PMID Version="1">22075171</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Discov. 2011 Oct;1(5):408-19</RefSource>
<PMID Version="1">22586631</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2012 Jun;13(6):607-15</RefSource>
<PMID Version="1">22575588</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2015 Sep;16(9):e424-5</RefSource>
<PMID Version="1">26370346</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2015 Sep;16(9):e423-4</RefSource>
<PMID Version="1">26370345</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2015 Sep;16(9):e422-3</RefSource>
<PMID Version="1">26370344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2015;350:h3198</RefSource>
<PMID Version="1">26067838</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2015 Jul;16(7):739-40</RefSource>
<PMID Version="1">26071348</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018290" MajorTopicYN="N">Cervical Intraepithelial Neoplasia</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003364" MajorTopicYN="N" Type="Geographic">Costa Rica</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D052162" MajorTopicYN="N">Human papillomavirus 16</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D052161" MajorTopicYN="N">Human papillomavirus 18</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D030361" MajorTopicYN="N">Papillomavirus Infections</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053918" MajorTopicYN="N">Papillomavirus Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS700097</OtherID>
<OtherID Source="NLM">PMC4498478</OtherID>
<InvestigatorList><Investigator ValidYN="Y"><LastName>Garland</LastName>
<ForeName>S M</ForeName>
<Initials>SM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Mindel</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Skinner</LastName>
<ForeName>S R</ForeName>
<Initials>SR</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>De Sutter</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Poppe</LastName>
<ForeName>W A J</ForeName>
<Initials>WA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tjalma</LastName>
<ForeName>W A A</ForeName>
<Initials>WA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>De Carvalho</LastName>
<ForeName>N S</ForeName>
<Initials>NS</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Naud</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Teixeira</LastName>
<ForeName>J C</ForeName>
<Initials>JC</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Aoki</LastName>
<ForeName>F Y</ForeName>
<Initials>FY</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Diaz-Mitoma</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ferguson</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Miller</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Papp</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ramjattan</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Romanowski</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Orr</LastName>
<ForeName>P H</ForeName>
<Initials>PH</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Apter</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Karppa</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Kudjoi</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lehtinen</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lönnberg</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Palmroth</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Paavonen</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Petaja</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tuomivaara</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Gent</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Grubert</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Höpker</LastName>
<ForeName>W D</ForeName>
<Initials>WD</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Peters</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schulze</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Schwarz</LastName>
<ForeName>T F</ForeName>
<Initials>TF</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Waddell</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Salmerón</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Crisostomo</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Del Rosario-Raymundo</LastName>
<ForeName>M R</ForeName>
<Initials>MR</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Raymundo</LastName>
<ForeName>J E</ForeName>
<Initials>JE</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Germar</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Limson</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Villanueva</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zamora</LastName>
<ForeName>J D</ForeName>
<Initials>JD</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bajo-Arenas</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bayas</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Campins</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Castellsagué</LastName>
<ForeName>X</ForeName>
<Initials>X</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Castro</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Centeno</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rodríguez de la Pinta</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Torné</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Vidart</LastName>
<ForeName>J A</ForeName>
<Initials>JA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chow</LastName>
<ForeName>S N</ForeName>
<Initials>SN</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Yu</LastName>
<ForeName>M H</ForeName>
<Initials>MH</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Cruickshank</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hakim</LastName>
<ForeName>E A</ForeName>
<Initials>EA</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lewis</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Szarewski</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Ackerman</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Caldwell</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chambers</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Chatterjee</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>DeMars</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fine</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Huh</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Klein</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lalezari</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Leeman</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Luber</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Martens</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Peterson</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rosen</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Seidman</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sperling</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stager</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Stapleton</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Waldbaum</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wheeler</LastName>
<ForeName>C M</ForeName>
<Initials>CM</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Colau</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Genevrois</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Martens</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Houard</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Poncelet</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Provenzano</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tonglet</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Van Hoof</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Descamps</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Hardt</LastName>
<ForeName>K</ForeName>
<Initials>K</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Xhenseval</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Zahaf</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Alt</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Iskaros</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Limaye</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Luff</LastName>
<ForeName>R D</ForeName>
<Initials>RD</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>McNeeley</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Winkler</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Molijn</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Quint</LastName>
<ForeName>W</ForeName>
<Initials>W</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Struijk</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Van de Sandt</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Van Doorn</LastName>
<ForeName>L J</ForeName>
<Initials>LJ</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Klugman</LastName>
<ForeName>K P</ForeName>
<Initials>KP</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nieminen</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Bergeron</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Eisenstein</LastName>
<ForeName>E</ForeName>
<Initials>E</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Karron</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Marks</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Nolan</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Tay</LastName>
<ForeName>S K</ForeName>
<Initials>SK</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year>
<Month>02</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>04</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>04</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>6</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>6</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26071347</ArticleId>
<ArticleId IdType="pii">S1470-2045(15)00047-9</ArticleId>
<ArticleId IdType="doi">10.1016/S1470-2045(15)00047-9</ArticleId>
<ArticleId IdType="pmc">PMC4498478</ArticleId>
<ArticleId IdType="mid">NIHMS700097</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>Belgique</li>
<li>France</li>
<li>Philippines</li>
<li>États-Unis</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Maryland</li>
<li>Nouveau-Mexique</li>
<li>Rhône-Alpes</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Lyon</li>
<li>Melbourne</li>
</settlement>
<orgName><li>Université de Melbourne</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Bosch, F Xavier" sort="Bosch, F Xavier" uniqKey="Bosch F" first="F Xavier" last="Bosch">F Xavier Bosch</name>
<name sortKey="Castellsague, Xavier" sort="Castellsague, Xavier" uniqKey="Castellsague X" first="Xavier" last="Castellsague">Xavier Castellsague</name>
<name sortKey="Chatterjee, Archana" sort="Chatterjee, Archana" uniqKey="Chatterjee A" first="Archana" last="Chatterjee">Archana Chatterjee</name>
<name sortKey="Chow, Song Nan" sort="Chow, Song Nan" uniqKey="Chow S" first="Song-Nan" last="Chow">Song-Nan Chow</name>
<name sortKey="Descamps, Dominique" sort="Descamps, Dominique" uniqKey="Descamps D" first="Dominique" last="Descamps">Dominique Descamps</name>
<name sortKey="Diaz Mitoma, Francisco" sort="Diaz Mitoma, Francisco" uniqKey="Diaz Mitoma F" first="Francisco" last="Diaz-Mitoma">Francisco Diaz-Mitoma</name>
<name sortKey="Dubin, Gary" sort="Dubin, Gary" uniqKey="Dubin G" first="Gary" last="Dubin">Gary Dubin</name>
<name sortKey="Germar, Maria Julieta" sort="Germar, Maria Julieta" uniqKey="Germar M" first="Maria Julieta" last="Germar">Maria Julieta Germar</name>
<name sortKey="Gonzalez, Paula" sort="Gonzalez, Paula" uniqKey="Gonzalez P" first="Paula" last="González">Paula González</name>
<name sortKey="Harper, Diane M" sort="Harper, Diane M" uniqKey="Harper D" first="Diane M" last="Harper">Diane M. Harper</name>
<name sortKey="Jimenez, Silvia" sort="Jimenez, Silvia" uniqKey="Jimenez S" first="Silvia" last="Jiménez">Silvia Jiménez</name>
<name sortKey="Lewis, David J M" sort="Lewis, David J M" uniqKey="Lewis D" first="David J M" last="Lewis">David J M. Lewis</name>
<name sortKey="Limson, Genara" sort="Limson, Genara" uniqKey="Limson G" first="Genara" last="Limson">Genara Limson</name>
<name sortKey="Lowy, Douglas R" sort="Lowy, Douglas R" uniqKey="Lowy D" first="Douglas R" last="Lowy">Douglas R. Lowy</name>
<name sortKey="Naud, Paulo" sort="Naud, Paulo" uniqKey="Naud P" first="Paulo" last="Naud">Paulo Naud</name>
<name sortKey="Peters, Klaus" sort="Peters, Klaus" uniqKey="Peters K" first="Klaus" last="Peters">Klaus Peters</name>
<name sortKey="Pinto, Ligia A" sort="Pinto, Ligia A" uniqKey="Pinto L" first="Ligia A" last="Pinto">Ligia A. Pinto</name>
<name sortKey="Poppe, Willy A J" sort="Poppe, Willy A J" uniqKey="Poppe W" first="Willy A J" last="Poppe">Willy A J. Poppe</name>
<name sortKey="Porras, Caroline" sort="Porras, Caroline" uniqKey="Porras C" first="Caroline" last="Porras">Caroline Porras</name>
<name sortKey="Ramjattan, Brian" sort="Ramjattan, Brian" uniqKey="Ramjattan B" first="Brian" last="Ramjattan">Brian Ramjattan</name>
<name sortKey="Rodriguez, Ana Cecilia" sort="Rodriguez, Ana Cecilia" uniqKey="Rodriguez A" first="Ana Cecilia" last="Rodriguez">Ana Cecilia Rodriguez</name>
<name sortKey="Romanowski, Barbara" sort="Romanowski, Barbara" uniqKey="Romanowski B" first="Barbara" last="Romanowski">Barbara Romanowski</name>
<name sortKey="Safaeian, Mahboobeh" sort="Safaeian, Mahboobeh" uniqKey="Safaeian M" first="Mahboobeh" last="Safaeian">Mahboobeh Safaeian</name>
<name sortKey="Salmeron, Jorge" sort="Salmeron, Jorge" uniqKey="Salmeron J" first="Jorge" last="Salmeron">Jorge Salmeron</name>
<name sortKey="Schiffman, Mark" sort="Schiffman, Mark" uniqKey="Schiffman M" first="Mark" last="Schiffman">Mark Schiffman</name>
<name sortKey="Schiller, John T" sort="Schiller, John T" uniqKey="Schiller J" first="John T" last="Schiller">John T. Schiller</name>
<name sortKey="Schussler, John" sort="Schussler, John" uniqKey="Schussler J" first="John" last="Schussler">John Schussler</name>
<name sortKey="Schwarz, Tino F" sort="Schwarz, Tino F" uniqKey="Schwarz T" first="Tino F" last="Schwarz">Tino F. Schwarz</name>
<name sortKey="Sherman, Mark E" sort="Sherman, Mark E" uniqKey="Sherman M" first="Mark E" last="Sherman">Mark E. Sherman</name>
<name sortKey="Teixeira, Julio C" sort="Teixeira, Julio C" uniqKey="Teixeira J" first="Julio C" last="Teixeira">Julio C. Teixeira</name>
<name sortKey="Tjalma, Wiebren A A" sort="Tjalma, Wiebren A A" uniqKey="Tjalma W" first="Wiebren A A" last="Tjalma">Wiebren A A. Tjalma</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Kreimer, Aimee R" sort="Kreimer, Aimee R" uniqKey="Kreimer A" first="Aimée R" last="Kreimer">Aimée R. Kreimer</name>
</region>
<name sortKey="Hildesheim, Allan" sort="Hildesheim, Allan" uniqKey="Hildesheim A" first="Allan" last="Hildesheim">Allan Hildesheim</name>
<name sortKey="Wacholder, Sholom" sort="Wacholder, Sholom" uniqKey="Wacholder S" first="Sholom" last="Wacholder">Sholom Wacholder</name>
<name sortKey="Wheeler, Cosette M" sort="Wheeler, Cosette M" uniqKey="Wheeler C" first="Cosette M" last="Wheeler">Cosette M. Wheeler</name>
</country>
<country name="Belgique"><noRegion><name sortKey="Struyf, Frank" sort="Struyf, Frank" uniqKey="Struyf F" first="Frank" last="Struyf">Frank Struyf</name>
</noRegion>
<name sortKey="David, Marie Pierre" sort="David, Marie Pierre" uniqKey="David M" first="Marie-Pierre" last="David">Marie-Pierre David</name>
</country>
<country name="Philippines"><noRegion><name sortKey="Del Rosario Raymundo, Maria Rowena" sort="Del Rosario Raymundo, Maria Rowena" uniqKey="Del Rosario Raymundo M" first="Maria Rowena" last="Del Rosario-Raymundo">Maria Rowena Del Rosario-Raymundo</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Skinner, S Rachel" sort="Skinner, S Rachel" uniqKey="Skinner S" first="S Rachel" last="Skinner">S Rachel Skinner</name>
</noRegion>
<name sortKey="Garland, Suzanne M" sort="Garland, Suzanne M" uniqKey="Garland S" first="Suzanne M" last="Garland">Suzanne M. Garland</name>
</country>
<country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Herrero, Rolando" sort="Herrero, Rolando" uniqKey="Herrero R" first="Rolando" last="Herrero">Rolando Herrero</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C56 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002C56 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:26071347
   |texte=   Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:26071347" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki